论文部分内容阅读
目的:探讨Mirk/Dryk1b(Minibrain-related kinase/Dual specificity tyrosine-phosphorylation-regulated kinase1B)在卵巢组织中的表达及其临床意义。方法:利用免疫组化检测Mirk/Dyrk1b在30例上皮性卵巢癌、20例上皮性卵巢囊腺瘤、10例正常卵巢组织中的表达。结果:Dyrk1b在上皮性卵巢癌中的表达明显高于上皮性卵巢囊腺瘤及正常卵巢组织(P<0.05),而其在正常的卵巢组织中几乎不表达;Dyrk1b的阳性率与卵巢癌的组织学分化程度有明显的相关性(P<0.01),与卵巢癌的临床分期、有无淋巴转移等无明显相关性(P>0.05)。结论:Dyrk1b在上皮性卵巢癌中高表达,提示其可能参与了肿瘤的发生和发展,并有望成为临床早期诊断的肿瘤标志物和新的卵巢癌治疗的靶基因。
Objective: To investigate the expression and clinical significance of Mirk / Dryk1b (Minimal-related kinase / Dual specificity tyrosine-phosphorylation-regulated kinase1B) in ovarian tissue. Methods: Immunohistochemistry was used to detect the expression of Mirk / Dyrk1b in 30 cases of epithelial ovarian cancer, 20 cases of epithelial ovarian cystadenoma and 10 cases of normal ovarian tissue. Results: The expression of Dyrk1b in epithelial ovarian cancer was significantly higher than that in epithelial ovarian cystadenoma and normal ovarian tissue (P <0.05), but not in normal ovarian tissue. The positive rate of Dyrk1b was correlated with the There was a significant correlation between histological differentiation and clinical stage (P <0.01). There was no significant correlation between histological differentiation and lymph node metastasis (P> 0.05). Conclusion: The high expression of Dyrk1b in epithelial ovarian cancer suggests that it may be involved in the occurrence and development of tumors and is expected to be a tumor marker for early clinical diagnosis and a new target gene for ovarian cancer therapy.